ADVISORY/Abgenix's ABX-IL8 Antibody Associated With Statistically Significant Improvement in Psoriasis.Business Editors & Health/Medical Writers ADVISORY...for Monday (March 5) NOTE TO EDITORS: Multimedia Assets Available With This Story Include Graphics, Logos, Text News Releases --(BUSINESS WIRE) Abgenix Inc. (Nasdaq:ABGX) presented the results of its Phase IIa clinical trial of ABX-IL8 for use in the treatment of moderate-to-severe psoriasis psoriasis (sôrī`əsĭs), occasionally acute but usually chronic and recurrent inflammation of the skin. The exact cause is unknown, but the disease appears to be an inherited, possibly autoimmune disorder that causes the at a meeting of the American Academy of Dermatology The American Academy of Dermatology (AAD) is the largest organization of dermatologists in the world. The Academy grants Fellowships and Associate Memberships, as well as Fellowships for Nonresidents (of the United States of America or Canada). (AAD AAD American Academy of Dermatology. AAD American Association of Dermatology ) in Washington, D.C. You can reach the story directly by going to http://www.newstream.com/cgi-bin/display_story.cgi?2249 This multimedia news story is for free and unrestricted use on your news information site (and for print or broadcast too). Visit http://www.newstream.com to download To receive a file transmitted over a network. In any communications session, "download" means receive, and "upload" means send. The download/upload often implies a big/little scenario, in which data is being downloaded from the "big" server into the "little" user's computer. video, audio, text, graphics and photos. If you have any questions about the story, or about Newstream.com, please write to us at info@newstream.com. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion